UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038228
Receipt number R000043017
Scientific Title Evaluation of serum nestin levels for diagnosis and disease activity in lung cancer patients
Date of disclosure of the study information 2019/10/17
Last modified on 2023/04/10 18:48:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of serum nestin levels for diagnosis and disease activity in lung cancer patients

Acronym

Evaluation of nestin in lung cancer

Scientific Title

Evaluation of serum nestin levels for diagnosis and disease activity in lung cancer patients

Scientific Title:Acronym

Evaluation of nestin in lung cancer

Region

Japan


Condition

Condition

Lung cancer

Classification by specialty

Pneumology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the diagnostic usefulness of serum nestin levels in patients with lung cancer. Especially for patients with small cell lung cancer, serum nestin is measured over time to evaluate the relationship between treatment response and prognosis.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

Relationship between serum nestin level and disease activigy in small cell lung cacner patients.

Key secondary outcomes

Evaluation of diagnostic significance of serum nestin level at the time of lung cancer diagnosis. Relationship between serum nestin levels and therapeutic response in small cell lung cancer.


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients diagnosed with lung cacner at Nagoya City University Hospital.
Patients with obtaining written informed consent.

Key exclusion criteria

Pregnant women and women with the possibility of pregnancy.
Patients with other malignant tumors.

Target sample size

120


Research contact person

Name of lead principal investigator

1st name Ken
Middle name
Last name Maeno

Organization

Nagoya City University Graduate School of Medical Sciences

Division name

Department of Respiratory Medicine, Allergy and Clinical Immunology

Zip code

467-8601

Address

1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi

TEL

0528538216

Email

k.maeno@med.nagoya-cu.ac.jp


Public contact

Name of contact person

1st name Ken
Middle name
Last name Maeno

Organization

Nagoya City University Graduate School of Medical Sciences

Division name

Respiratory Medicine, Allergy and Clinical Immunology

Zip code

467-8601

Address

1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi

TEL

0528538216

Homepage URL


Email

k.maeno@med.nagoya-cu.ac.jp


Sponsor or person

Institute

Nagoya City University

Institute

Department

Personal name



Funding Source

Organization

Japan Society for the Promotion of Science

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagoya City University Graduate School of Medical Sciences

Address

1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi

Tel

0528538216

Email

k.maeno@med.nagoya-cu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 10 Month 17 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2019 Year 03 Month 11 Day

Date of IRB

2019 Year 03 Month 11 Day

Anticipated trial start date

2019 Year 04 Month 01 Day

Last follow-up date

2024 Year 03 Month 31 Day

Date of closure to data entry

2024 Year 03 Month 31 Day

Date trial data considered complete

2024 Year 03 Month 31 Day

Date analysis concluded

2024 Year 03 Month 31 Day


Other

Other related information

No paticular related information


Management information

Registered date

2019 Year 10 Month 07 Day

Last modified on

2023 Year 04 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043017


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name